Trial Profile

A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Aug 2025 According to a media release, 50 patients have been treated at dose levels up to 1200 ug/kg in the dose-escalation and expansion phase 1 trial evaluating the therapy for relapsed or refractory multiple myeloma (MM).
25 Aug 2025 According to a Nanjing Leads Biolabs media release, today announced the first patient has been successfully dosed in the Phase II trial of LBL-034 following strong Phase I data.
13 May 2025 Planned number of patients changed from 418 to 342.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com